Scholarlink

<p>Altered choline, glutamine, and glucose metabolism form a triumvirate of metabolic reprogramming in most cancers that significantly influences growth, progression, and response to treatment. Photoimmunotherapy (PIT) is a highly target-specific treatment where a targeting antibody (Ab) is conjugated to a photosensitizing dye, IR700, that damages the target only when exposed to near-infrared (NIR) light irradiation. The requirement of an extracellular target has restricted PIT targeting to cell surface receptors and antigens. Here, for the first time, we exploited the extracellular domain of three metabolic transporters, CTL1 for choline, ASCT2 for glutamine, and GLUT1 for glucose for PIT, to demonstrate metabolotheranostics of cancer cells. We analyzed the TCGA database to establish increased expression of the three transporters in human pancreatic ductal adenocarcinoma (PDAC). For the PIT studies, we used two patient-derived PDAC cell lines selected for differences in transporter expression and demonstrated an expression-dependent reduction of cell viability following PIT. A single CTL1-PIT treatment of Pa04C tumors resulted in the eradication of four out of five established tumors. In PDAC, the PIT of metabolic transporters would be most effective in the intraoperative setting, where it could significantly impact cancer cells that may have invaded critical structures.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Metabolotheranostics of pancreatic cancer by targeting choline, glutamine, and glucose transporters with photoimmunotherapy

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月21日

查看全文
  • Puneet Khandelwal,
  • Jiefu Jin,
  • James D. Barnett,
  • Yelena Mironchik,
  • Balaji Krishnamachary,
  • Saleem Yousf,
  • Raj Kumar Sharma,
  • Hisataka Kobayashi,
  • Zaver M. Bhujwalla

摘要

Altered choline, glutamine, and glucose metabolism form a triumvirate of metabolic reprogramming in most cancers that significantly influences growth, progression, and response to treatment. Photoimmunotherapy (PIT) is a highly target-specific treatment where a targeting antibody (Ab) is conjugated to a photosensitizing dye, IR700, that damages the target only when exposed to near-infrared (NIR) light irradiation. The requirement of an extracellular target has restricted PIT targeting to cell surface receptors and antigens. Here, for the first time, we exploited the extracellular domain of three metabolic transporters, CTL1 for choline, ASCT2 for glutamine, and GLUT1 for glucose for PIT, to demonstrate metabolotheranostics of cancer cells. We analyzed the TCGA database to establish increased expression of the three transporters in human pancreatic ductal adenocarcinoma (PDAC). For the PIT studies, we used two patient-derived PDAC cell lines selected for differences in transporter expression and demonstrated an expression-dependent reduction of cell viability following PIT. A single CTL1-PIT treatment of Pa04C tumors resulted in the eradication of four out of five established tumors. In PDAC, the PIT of metabolic transporters would be most effective in the intraoperative setting, where it could significantly impact cancer cells that may have invaded critical structures.